Filgrastim induced thrombocytopenia

Kango, Ghazal; Haroun, Faysal

doi:10.1136/bcr-2020-234584

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Internal formula validation in our centre evidenced several benefits. Despite the fact that using the formula resulted in an increase of TBVs processed in most groups of patients, as a consequence, it was possible to reduce the number of aphereses in individuals younger than 60 years; this led to a lower use of G-CSF and plerixafor with the consequent lower exposure to adverse effects of these drugs [17][18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Prediction of blood volume to be processed to achieve a target number of CD34+ cells: Development, validation and implementation of a formula

et al. 2023

View full text Add to dashboard Cite

Background and Objectives Calculation of blood volume (BV) to be processed to achieve the target number of CD34+ cells can be accomplished by using collection efficiency 2 (CE2) formula. Our aim was to develop a BV web formula. Materials and Methods We calculated CE2 from aphereses performed between January 2015 and March 2020 in allogeneic donors and patients. From May 2020 to May 2021, we validated a formula: BV = ((Target CD34+ cells in the product)/(CD34+ pre‐apheresis cells × CE2)) × 100. Subsequently, we compared the outcome of the procedures carried out before formula implementation (pre‐formula), when standard three total BV collection was performed. Results CE2 was assessed in 384 apheresis procedures before formula implementation. CE2 was higher in allogeneic donors than in patients (53% ± 17% vs. 48% ± 15%, p = 0.008). CE2 was higher in multiple myeloma and non‐Hodgkin lymphoma than Hodgkin's lymphoma (48% ± 15%, 48% ± 15% and 42% ± 13%, respectively; p = 0.008). Our formula (available on a website: Publisheet) was prospectively used in 54 individuals. The formula was very accurate: predicted versus observed CD34 + cells/kg collected had an r‐value of 0.89 (p < 0.0001). We compared their results with 78 pre‐formula individuals. In the post‐formula group, a greater BV was processed in patients and less BV in allogeneic donors. Among individuals under 60 years of age, it was significantly less frequent than the need for more than one apheresis in the post‐formula group. Conclusion Formula calculations were accurate. Formula implementation allowed the optimization of the procedures and reduced the rate of individuals in need of apheresis for more than 1 day.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of blood volume to be processed to achieve a target number of CD34+ cells: Development, validation and implementation of a formula

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Other possible side effects refer to pulmonary involvement ranging from respiratory failure due [38] to interstitial pneumonia [39][40][41][42][43][44] (mostly due to increased toxicity of other drugs), or hepatic [45][46][47], renal [19,48,49] (with transient hematuria [50] during long-term treatment), and hematologic symptoms [51][52][53][54][55][56][57].…”

Section: Adverse Reactions To G-csfmentioning

confidence: 99%

Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor)

Bumbăcea,

Udrea,

Ali

et al. 2024

IJMS

View full text Add to dashboard Cite

Human granulocyte colony-stimulating factor (G-CSF) is a granulopoietic growth factor used in the treatment of neutropenia following chemotherapy, myeloablative treatment, or healthy donors preparing for allogeneic transplantation. Few hypersensitivity reactions (HRs) have been reported, and its true prevalence is unknown. We aimed to systematically characterize G-CSF-induced HRs while including a comprehensive list of adverse reactions. We reviewed articles published before January 2024 by searching in the PubMed, Embase, Cochrane Library, and Web of Science databases using a combination of the keywords listed, selected the ones needed, and extracted relevant data. The search resulted in 68 entries, 17 relevant to our study and 7 others found from manually searching bibliographic sources. A total of 40 cases of G-CSF-induced HR were described and classified as immediate (29) or delayed (11). Immediate ones were mostly caused by filgrastim (13 minimum), with at least 9 being grade 5 on the WAO anaphylaxis scale. Delayed reactions were mostly maculopapular exanthemas and allowed for the continuation of G-CSF. Reactions after first exposure frequently appeared and were present in at least 11 of the 40 cases. Only five desensitization protocols have been found concerning the topic at hand in the analyzed data. We believe this study brings to light the research interest in this topic that could benefit from further exploration, and propose regular updating to include the most recently published evidence.

show abstract

Multiple drugs

2020

Reactions Weekly

View full text Add to dashboard Cite

Filgrastim induced thrombocytopenia

Cited by 5 publications

References 14 publications

Prediction of blood volume to be processed to achieve a target number of CD34+ cells: Development, validation and implementation of a formula

Prediction of blood volume to be processed to achieve a target number of CD34+ cells: Development, validation and implementation of a formula

Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor)

Multiple drugs

Contact Info

Product

Resources

About